Release Date: 14-Feb-2023
Since the approval of the first bispecific antibody in 2009, this novel class of antibodies has taken the market up by the storm as more bispecific antibodies are entering the clinical pipeline and getting approved for a variety of indications. Out of all the commercialized bispecific antibodies, Hemlibra has undoubtedly been the most successful, with its sales exceeding a billion every year. Roche reported Hemlibra sales worth CHF 3.82 Billion (US$ 4.13 Billion) in the year 2022, which has been the highest since its approval. Among the newly approved antibodies, Vabysmo, also by Roche, has demonstrated significant sales figured in the first 11 months of 2022 post its approval. Meanwhile in China, Akeso has emerged as one of the front runners in the development of novel bispecific antibodies, with the NMPA approval of Cadonilimab, the first-in-class PD-1/CTLA-4 bispecific antibody. A new era has begun in development of antibodies, with many innovative bispecific antibodies entering the pipelines globally.
Download Global Bispecific Antibody Market Report 2028: